On Monday, Hindustan Construction Company Ltd (NSE:HCC)’s shares declined -3.48% to $22.20.
HCC Insurance Holdings, Inc. (HCC) released results for its second quarter ended June 30, 2015.
Net earnings were $80.4 million, or $0.84 per diluted share, in the second quarter of 2015, contrast to $97.1 million, or $0.97 per diluted share, in the same quarter of 2014. Net earnings were $193.3 million, or $2.01 per diluted share, in the first six months of 2015, as compared to $205.0 million, or $2.04 per diluted share, in the same period of 2014. Net earnings in 2015 comprised of after-tax losses from our recently attained Agriculture business (ProAg) of $2.2 million, or $0.02 per share, in second quarter and $9.9 million, or $0.10 per share, in the first six months.
Net earnings also comprised of after-tax foreign currency expense of $6.7 million, or $0.07 per share, in the second quarter of 2015, contrast to $1.8 million, or $0.02 per share, in the same quarter of 2014. This result partially reversed the $11.7 million after-tax foreign currency benefit recorded in the first quarter of 2015. Foreign currency benefit/expense is excluded from operating earnings(a), which were $86.8 million, or $0.91 per diluted share, in the second quarter of 2015, contrast to $95.7 million, or $0.95 per diluted share, in the same quarter of 2014.
HCC Insurance Holdings, Inc. underwrites non-correlated specialty insurance products worldwide. The company operates in five segments: U.S. Property & Casualty, Professional Liability, Accident & Health, U.S. Surety & Credit, and International. The U.S. Property & Casualty segment provides aviation, primary and excess casualty, small account errors and omissions (E&O) liability, employment practices liability (EPLI), disability, contingency, public risk, technical and construction property, title and mortgage reinsurance, residual value, and brown water marine products in the United States. The Professional Liability segment offers directors and officers (D&O) liability, large account E&O liability, fiduciary liability, fidelity and bankers blanket bonds, EPLI, transactional insurance, and cyber liability in the United States and internationally. The Accident & Health segment provides medical stop-loss, and short-term domestic and international medical coverages in the United States.
Pacific Ethanol Inc (NASDAQ:PEIX)’s shares gained 8.23% to $7.89.
Pacific Ethanol, Inc. (PEIX), a leading producer and marketer of low-carbon renewable fuels in the United States, stated its financial results for the three- and six-months ended June 30, 2015.
Second quarter 2015 Financial Highlights
- Net sales of $227.6 million
- Gross profit of $6.3 million
- Operating income of $2.3 million
- EPS of $0.03
- Adjusted EBITDA of $5.4 million
- Record total gallons sold of 140.7 million
Pacific Ethanol, Inc. produces and markets low-carbon renewable fuels in the Western United States. It sells ethanol primarily to gasoline refining and distribution companies. The company also provides ethanol transportation, storage, and delivery services through third-party service providers. In addition, it markets ethanol co-products, counting wet distiller grains and syrup to dairy operators and animal feed distributors; and corn oil to poultry and biodiesel customers.
At the end of Monday’s trade, Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)‘s shares surged 1.81% to $22.48.
Momenta Pharmaceuticals, Inc. (MNTA) stated its financial results for the second quarter ended June 30, 2015.
For the second quarter of 2015, the Company stated total revenues of $44.9 million, compriseing primarily of product and milestone revenues regardingthe approval and launch of GlatopaTM (glatiramer acetate injection). Momenta stated a net loss of $(2.2) million, or $(0.04) per share for the second quarter contrast to a net loss of $(26.2) million, or $(0.51) per share for the same period in 2014. At June 30, 2015, the Company had cash, cash equivalents, and marketable securities of $377.2 million.
Second Quarter Highlights and Recent Events
Complex Generics:
GlatopaTM, generic version of daily COPAXONE® 20 mg (glatiramer acetate injection)
- On April 16, 2015, Glatopa was approved by the FDA as the first and only “AP-rated,” substitutable generic version of daily COPAXONE 20 mg.
- On June 18, 2015, the U.S. Court of Appeals for the Federal Circuit (CAFC) again found the remaining patent on daily COPAXONE 20 mg at issue in Teva’s infringement suit to be invalid.
- Sandoz launched Glatopa on June 18, 2015. In the second quarter of 2015, Momenta recorded $19.2 million in product revenues from Glatopa sales, net of a deduction of $9.0 million for reimbursement to Sandoz of the Company’s share of pre-launch Glatopa-related legal expenses.
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases. The company’s complex generics programs comprise Enoxaparin sodium injection, a generic version of Lovenox that is used for the prevention and treatment of deep vein thrombosis, and to support the treatment of acute coronary syndromes; and M356, a generic version of Copaxone, which is a complex drug compriseing of a synthetic mixture of polypeptide chains for the treatment of patients with relapsing-remitting multiple sclerosis. Its biosimilars programs comprise M923, a biosimilar for rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and psoriasis; M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis; and other biosimilar programs.
NCR Corporation (NYSE:NCR), ended its Monday’s trading session with 2.52% gain, and closed at $27.68.
NCR Corporation ( NCR), the global leader in consumer transaction technologies, has been named among America’s most reputable companies in the technology industry, according to a new list released by Reputation Institute. NCR ranked #7 overall on the 2015 list of America’s top 25 most reputable technology companies, ahead of some of the most recognizable brands in the world.
Compiled annually by Reputation Institute, the world’s foremost research and advisory firm focused solely on corporate reputations, the list of America’s top 25 most reputable technology companies is derived from the data collected for the US RepTrak® 100 study.
The 2015 US RepTrak® 100 examines perceptions of companies by the US general public based on over 50,000 interviews. Reputation Institute’s RepTrak® model is the gold standard for reputation measurement, providing a one-of-a-kind measurement of how the public views the world’s best-known companies. The RepTrak® database is normative, examining 15 stakeholder groups in more than 25 industries and more than 50 countries for more than 7,000 companies.
NCR Corporation, a technology company, provides solutions and services that enable businesses to connect, interact, and transact with their customers worldwide. The company operates through four segments: Financial Services, Retail Solutions, Hospitality, and Emerging Industries.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
